The Medtronic MiniMed 770G System is the first FDA-approved hybrid closed-loop system that monitors glucose and automatically adjusts the delivery of long-acting or basal insulin based on the user’s glucose reading in users two years and up. Smart Guard Auto Mode automatically adjusts insulin delivery. It helps predict highs and lows in advance and increases or decreases insulin delivery. Now with smartphone connectivity.

Medtronic MiniMed 770G System Features

FDA-approved

The Medtronic MiniMed 770G System is the first FDA cleared, hybrid closed-loop system that monitors glucose and automatically adjusts the delivery of long-acting or basal insulin based on the user’s glucose reading in users two years and above. The advanced MiniMed  770G System integrates the SmartGuard ™ algorithm for comprehensive high and low treatment. It is the very first insulin pump that automatically adjusts for the basal insulin demand and at meals with the real-time glucose readings obtained by the Guardian  Sensor 3 CGM. It features an instinctive touchscreen user interface, enhanced Bluetooth connectivity to integrate the device with mobile apps, and multiple and flexible infusion choices. The MiniMed 770G allows for a complete solution toward effective diabetes management, offering improved convenience and confidence through an advanced integrated system of alerts and alarms, long battery life, and real-time monitoring.